Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission
María Agustina Perusini(University Health Network), Dennis Dong Hwan Kim(University Health Network), Ana Inés Varela(Hospital Ramos Mejía), Anežka Kvetková(Masaryk University), Ivana Ježíšková(Masaryk University), Kátia Bórgia Barbosa Pagnano(Universidade Estadual de Campinas (UNICAMP)), Beatriz Moiraghi(Hospital Ramos Mejía), Ana Beatriz Pascoal Lopes(Universidade Estadual de Campinas (UNICAMP)), Jiřı́ Mayer(Masaryk University), Amirthagowri Ambalavanan(Queen's University), Daniela Žáčková(Masaryk University), Michele Bianchini(Instituto Alexander Fleming), Cármino Antônio De Souza(Universidade Estadual de Campinas (UNICAMP)), Jessie J.F. Medeiros(Ontario Institute for Cancer Research), Carmen Fava, Danielle Pyne(University Health Network), Anthea Travas(University Health Network), Jaeyoon Kim(LG (United States)), Gislaine Borba Oliveira(Universidade Estadual de Campinas (UNICAMP)), Tomáš Jurček(Masaryk University), Carolina Pavlovsky(Unknown), Sagi Abelson(Ontario Institute for Cancer Research)
Cited by 0
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2010|1k
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2007|556